Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 11/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | FPR2 | P25090 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4638154 | 0.94 | CNR1 (0.72) | CNR1KMT2AMEN1HTTFPR2 | |
| SCHEMBL4637247 | 0.92 | CNR1 (0.57) | CNR1KMT2ASMN1; SMN2MEN1LMNA | |
| SCHEMBL4637371 | 0.92 | CNR1 (0.69) | CNR1KMT2ASMN1; SMN2MEN1LMNA | |
| SCHEMBL4901257 | 0.91 | CNR1 (0.60) | CNR1KMT2AMEN1LMNAMAPT | |
| SCHEMBL4637254 | 0.91 | CNR1 (0.72) | CNR1KMT2ASMN1; SMN2MEN1LMNA | |
| SCHEMBL4901135 | 0.90 | CA2 (0.64) | CNR1KMT2ASMN1; SMN2CA12CA1 | |
| SCHEMBL4637704 | 0.89 | CNR1 (0.71) | CNR1KMT2ASMN1; SMN2MEN1LMNA | |
| SCHEMBL4899334 | 0.88 | HTT (0.62) | CNR1KMT2ASMN1; SMN2MEN1LMNA | |
| SCHEMBL4901783 | 0.85 | KMT2A (0.63) | CNR1KMT2ASMN1; SMN2MEN1LMNA | |
| SCHEMBL4637362 | 0.84 | CNR1 (0.62) | CNR1KMT2ASMN1; SMN2MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009477-A1 | Arylalkyl Ureas As Cb1 Antagonists | NEUROGEN CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009477-A1 | Arylalkyl Ureas As Cb1 Antagonists | NEUROGEN CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009477-A1 | Arylalkyl Ureas As Cb1 Antagonists | NEUROGEN CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009477-A1 | Arylalkyl Ureas As Cb1 Antagonists | CNR1, CNR2, GPR119 | CNR1 1/4885KMT2A 1756/4885SMN1; SMN2 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.